unspecified compound 1

The term "unspecified compound 1" refers to one of the six candidate therapeutic agents evaluated in a phenotypic screening study using a GBA1 knock-out (KO) medaka (Oryzias latipes) model. This research, presented at the MDS Virtual Congress 2021 by investigators from Kyoto University, aimed to identify disease-modifying treatments for GBA1-related α-synucleinopathy, a category that includes Parkinson's disease and neuronopathic Gaucher's disease. The screening process involved administering compounds to the medaka from four weeks post-fertilization, prior to the onset of motor symptoms, to assess their impact on survival rates. While the study reported that two of the six tested compounds significantly prolonged survival and two worsened it, the specific chemical identities, structures, or code names of these compounds were not disclosed in the published abstract.